Zealand Pharma stock suffered its two worst days on record. Here's what's next for the weight loss drugmaker

Zealand Pharma faced setbacks as survodutide disappointed on dropout rates, prompting analysts to reassess the company’s obesity strategy. Despite that, sentiment remains constructive around its amylin-based candidate petrelintide, which analysts still view favorably. The article is mainly a qualitative read-through on pipeline risk and investor expectations rather than a new quantitative catalyst.

Analysis

Zealand Pharma faced setbacks as survodutide disappointed on dropout rates, prompting analysts to reassess the company’s obesity strategy. Despite that, sentiment remains constructive around its amylin-based candidate petrelintide, which analysts still view favorably. The article is mainly a qualitative read-through on pipeline risk and investor expectations rather than a new quantitative catalyst.